Greenwich lifesciences llc
WebApr 12, 2024 · Greenwich LifeSciences (NASDAQ:GLSI – Get Rating) had its price objective reduced by stock analysts at HC Wainwright from $78.00 to $38.00 in a research report issued to clients and investors on Monday, The Fly reports. ... Walleye Capital LLC bought a new stake in shares of Greenwich LifeSciences in the second quarter worth … WebMar 8, 2024 · Greenwich LifeSciences is getting ready to launch Phase 3 trials for its breast cancer treatment March 8, 2024 By Sarah Smith , Editor-in-Chief, InvestorPlace.com Mar 8, 2024, 3:15 pm EST March 8 ...
Greenwich lifesciences llc
Did you know?
WebApr 11, 2024 · NASDAQ:GLSI opened at $12.65 on Monday. Greenwich LifeSciences has a 52 week low of $6.82 and a 52 week high of $21.50. The stock’s fifty day moving average is $15.24 and its two-hundred day ... WebApr 14, 2024 · Shares of Greenwich LifeSciences stock opened at $11.97 on Friday. The company has a market capitalization of $153.81 million, a price-to-earnings ratio of -21.00 and a beta of 0.93. Greenwich ...
WebInsiders own 39% of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) shares but retail investors control 42% of the company. Simply Wall St. WebDec 9, 2024 · Greenwich LifeScience stock skyrockets more than 2,000% after upbeat data on breast cancer treatment Published: Dec. 9, 2024 at 2:29 p.m. ET ... -0.03%. Shares of Greenwich LifeSciences Inc. GLSI ...
WebApr 12, 2024 · Greenwich LifeSciences ( NASDAQ:GLSI – Get Rating) had its price objective reduced by stock analysts at HC Wainwright from $78.00 to $38.00 in a … WebFind the latest Greenwich LifeSciences, Inc. (GLSI) stock quote, history, news and other vital information to help you with your stock trading and investing.
WebGreenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who ...
WebApr 13, 2024 · Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) VP Jaye Thompson purchased 1,000 shares of the firm’s stock in a transaction dated Tuesday, April 11th.The shares were bought at an average price of $11.87 per share, for a total transaction of $11,870.00. Following the completion of the transaction, the vice president now owns … baron kurumanWebApr 11, 2024 · Greenwich LifeSciences has a 1-year low of $6.82 and a 1-year high of $21.50. The business has a 50-day moving average price of $15.24 and a 200 day … baron landscaping wilmerding paWebJul 12, 2024 · Greenwich Lifesciences (NASDAQ: GLSI) stock is heading higher on Tuesday after the U.S. Food and Drug Administration (FDA) lifted a hold on a Phase III clinical trial.. That hold from the FDA was ... baron lampenWebDec 9, 2024 · Well, Greenwich is a clinical-stage biopharmaceutical company that calls Texas its home. And importantly, Greenwich is behind a new treatment to prevent … suzuki s40 cafe racer kitWebApr 6, 2024 · According to the current price, Greenwich LifeSciences is 190.84% away from the 52-week low. What was the 52-week high for Greenwich LifeSciences stock? The … baron lambert ophtalmologieWebApr 14, 2024 · On Friday, March 10th, Snehal Patel bought 1,000 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $12.12 per share, with a total value of $12,120.00. baron lakeWebApr 13, 2024 · Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) VP Jaye Thompson purchased 1,000 shares of the firm’s stock in a transaction dated Tuesday, … suzuki s40 cafe racer